Posts by Sandra Ansanay-Alex
CSEM Single-Cell Omics Workshop
The CSEM Single Cell Omics Workshop is taking place on 2 December 2025 at Aquatis Hotel in Lausanne Next-gen single-cell omics workshop, is a one-day event at the forefront of bioconvergence that brings together pioneers and innovators from the pharma and biotech industries, clinical practice, start-ups, regulation, and research. Single-cell technologies are revolutionizing complex 3D…
Read MoreWho You Inherit From Matters: New Genetic Study Uncovers Parent-Specific Effects
A groundbreaking study led by the SIB Statistical Genetics Group (University of Lausanne and Unisanté) reveals that the same genetic variant can affect traits like height, metabolism, and disease risk differently depending on whether it’s inherited from the mother or father. Using a new computational method, researchers analyzed DNA from over 236,000 individuals across…
Read MoreSNSF – Starting Grant
Apply before from 1 February until 5 May 2026 for the Swiss National Science Foundation Starting Grant SNSF Starting Grants 2025 represent the SNSF’s highest level of career funding. The call enables researchers to carry out their own independent project and lead a research team in Switzerland. Applicants must have several years of research…
Read MoreSNSF – Ambizione
Apply before 4 November 2025 for the Swiss National Science Foundation Ambizione programme Ambizione grants are aimed at early career researchers who wish to conduct, manage and lead an independent project at a Swiss higher education institution. The scheme supports young researchers both from Switzerland and abroad. Scientists holding non-professorial academic positions at higher…
Read MoreThe Origin of Astrocytes Revealed
A major discovery in neuroscience: a study from the Faculty of Medicine (FacMed) and the Synapsy Center at the University of Geneva uncovers that cortical astrocytes originate from two distinct progenitor cell types. Long considered a uniform support cell population, astrocytes are now recognized as diverse and essential players in brain function, involved in…
Read MoreNovochizol’s AgrINovo Partnership: Swiss-Indian Alliance for Agricultural Innovation
Indian company Aquagri, its partner, and Novochizol SA, a Valais-based startup, announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide. Novochizol™ is derived from chitosan, made from chitin, the second most abundant polysaccharide…
Read MoreSwiss Health Valley Biotechs Advance Drug Pipelines with Promising Clinical Milestones
Three innovative biotech companies based in Western Switzerland, Stalicla, Legacy Healthcare and iOnctura, have recently achieved significant progress in their therapeutic pipelines, reinforcing the region’s position as a hub for health innovation. STALICLA: Advancing Precision Medicine for Autism Geneva-based STALICLA has received the green light from the U.S. Food and Drug Administration (FDA) to initiate…
Read MoreRelief Therapeutics is preparing a reverse merger with NeuroX, the successor to MindMaze
The merger must take the form of an exchange of all NeuroX shares for newly issued shares in Relief. The transaction, which is expected to be finalised before the end of the year, would value the Geneva-based company at CHF 100 million and its future partner at CHF 1 billion. The Geneva-based pharmaceutical company…
Read MoreAzureCell Therapies and Myriad Optics Awarded by Gebert Rüf Stiftung Innobooster Programme
Two Swiss Health Valley projects, from EPFL and University of Geneva, got a CHF 150’000 Innobooster grant from Gebert Rüf Stiftung programme: AzureCell Therapies and Myriad Optics. AzureCell Therapies | Bilal Fares, University of Geneva Every 9 min, a new patient is diagnosed with Parkinson’s, a condition long considered incurable due to the irreversible loss…
Read MoreBreaking Through Cancer’s Soft Defense: A Revolutionary Swiss Approach
Swiss researchers from EPFL, University of Geneva, and HUG hospitals are pioneering a groundbreaking strategy to overcome immunotherapy resistance by targeting cancer cells’ physical properties rather than their biology. The project received a CHF 1,4 million grant from Foundation Leenaards. “Our approach targets the mechanical properties of cancer cells by making their membranes stiffer, which…
Read More